Compare GSK plc (GSK) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Global X Lithium & Battery Tech ETF — how do they compare? GSK plc trades at $46.6 (market cap $91.88B), while Global X Lithium & Battery Tech ETF trades at $69.77 (market cap $1.45B). The key difference: GSK plc is far larger — about 63.4× Global X Lithium & Battery Tech ETF's market cap, and GSK plc pays a 3.9% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Global X Lithium & Battery Tech ETF for 56 Days on average.
| GSK | LIT | |
|---|---|---|
Market Cap | $91.88B | $1.45B |
Volume | 7,730,529 | 89,392 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $61.18 | $91.62 |
52-Week Low | $43.24 | $53.92 |
Typical Hold Time | 93 Days | 56 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
LIT (Global X Lithium & Battery Tech ETF) trades at $69.51, down 2.2% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. Recent news highlights significant short interest decline (53.1% drop in September 2026) and positive catalysts from EV adoption trends. The ETF's performance reflects ongoing volatility in lithium markets amid shifting commodity prices and global electrification policies.
Outlook remains driven by long-term EV growth, though near-term risks include lithium price volatility and geopolitical tensions. Investment opportunity lies in exposure to battery technology leaders, balanced by sector-specific supply chain and regulatory uncertainties that could impact shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
